Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- SSP Initiates Clinical Study on Antibacterial Eye Drops in US
February 24, 2003
- Sankyo, Fujisawa to Market Aventis' Telithromycin
February 24, 2003
- Testing Conditions Announced for 23rd Quality Reevaluation
February 24, 2003
- JSC Recommends Discontinuation of Intradermal Test for Antibacterials
February 24, 2003
- Kyowa Hakko Sets Up Antibody Biz House
February 24, 2003
- Physicians with Knowledge of Both Western and Oriental Medicine Needed: Kampo Symposium
February 24, 2003
- Eli Lilly Conducts Trial on Switching from Typical to Atypical Antipsychotic Drugs
February 24, 2003
- Pharma SNP Consortium to Complete Activities in May
February 24, 2003
- Singulair's Share Up Since Approval of Long-term Prescription: Banyu
February 24, 2003
- PRESS SEMINAR
February 24, 2003
- Novo Nordisk Pharma to Focus Harder on Diabetes: President Moore
February 24, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
February 24, 2003
- Sales of Anti-allergic Talion Set to Double in FY2002: Tanabe
February 24, 2003
- ESRI Report Recommends Unification of Social Insurance Programs
February 24, 2003
- MEDICAL DEVICE NEWS IN BRIEF
February 24, 2003
- Overseas Growth a Major Priority: Kyorin's President
February 24, 2003
- National Burden Rate to Drop to 36.1% in FY2003
February 24, 2003
- Matsumotokiyoshi Ties Up with Itayama Medico of Yamanashi
February 24, 2003
- 10 Wholesalers to Be Surcharged for Violation of Antimonopoly Act
February 24, 2003
- List of Drugs Announced for 24th Quality Reevaluation
February 24, 2003
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…